688506 百利天恒
已收盘 09-14 15:00:01
资讯
新帖
简况
9月14日百利天恒涨5.61%，中欧医疗健康混合A基金重仓该股
证券之星 · 09-14 16:37
9月14日百利天恒涨5.61%，中欧医疗健康混合A基金重仓该股
百利天恒涨5.61%，开源证券二周前给出“买入”评级
证券之星 · 09-14 16:37
百利天恒涨5.61%，开源证券二周前给出“买入”评级
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren（HER2 ADC）在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告》
证券之星 · 09-14 01:05
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren（HER2 ADC）在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告》
百利天恒最新公告：T-Bren联合帕妥珠单抗III期临床试验完成首例受试者入组
证券之星 · 09-13 15:39
百利天恒最新公告：T-Bren联合帕妥珠单抗III期临床试验完成首例受试者入组
每周股票复盘：百利天恒（688506）宜泽康III期临床完成首例入组
证券之星 · 09-13 01:46
每周股票复盘：百利天恒（688506）宜泽康III期临床完成首例入组
百利天恒（688506）披露宜泽康®III期临床试验完成首例受试者入组，9月10日股价上涨2.2%
证券之星 · 09-10
百利天恒（688506）披露宜泽康®III期临床试验完成首例受试者入组，9月10日股价上涨2.2%
百利天恒：宜泽康III期临床试验完成首例受试者入组
同花顺 · 09-09
百利天恒：宜泽康III期临床试验完成首例受试者入组
百利天恒跌3.34% 招商证券在历史大顶发研报强烈推荐
中金财经 · 09-08
百利天恒跌3.34% 招商证券在历史大顶发研报强烈推荐
百利天恒：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
证券日报网 · 09-06
百利天恒：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
开源证券：给予百利天恒买入评级
证券之星 · 08-28
开源证券：给予百利天恒买入评级
百利天恒（688506）2026年中报简析：增收不增利，三费占比上升明显
证券之星 · 08-28
百利天恒（688506）2026年中报简析：增收不增利，三费占比上升明显
百利天恒连亏1年半 两募资共47.5亿元IPO国投证券保荐
中金财经 · 08-27
百利天恒连亏1年半 两募资共47.5亿元IPO国投证券保荐
百利天恒四闯港股：业绩过山车亏损加剧，董秘与证代接连离职
市场资讯 · 08-27
百利天恒四闯港股：业绩过山车亏损加剧，董秘与证代接连离职
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）用于局部晚期、复发或转移性HR+HER2-乳腺癌的III期临床试验的期中分析达到主要终点的公告》
证券之星 · 08-27
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）用于局部晚期、复发或转移性HR+HER2-乳腺癌的III期临床试验的期中分析达到主要终点的公告》
百利天恒最新公告：上半年净亏损16.37亿元
证券之星 · 08-26
百利天恒最新公告：上半年净亏损16.37亿元
百利天恒最新公告：宜泽康®乳腺癌III期临床达主要终点
证券之星 · 08-25
百利天恒最新公告：宜泽康®乳腺癌III期临床达主要终点
百利天恒：宜泽康现有产能可充分满足现阶段国内商业化与国内外临床需求
证券之星 · 08-24
百利天恒：宜泽康现有产能可充分满足现阶段国内商业化与国内外临床需求
每周股票复盘：百利天恒（688506）BL-B01D1期中分析达主要终点
证券之星 · 08-23
每周股票复盘：百利天恒（688506）BL-B01D1期中分析达主要终点
百利天恒依据首例给药临床试验确认17亿元里程碑收入，BMS尚未打款缺少实质性临床终点数据
市场资讯 · 08-21
百利天恒依据首例给药临床试验确认17亿元里程碑收入，BMS尚未打款缺少实质性临床终点数据
百利天恒最新公告：双抗ADC肺癌III期临床达主要终点
证券之星 · 08-17
百利天恒最新公告：双抗ADC肺癌III期临床达主要终点
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":252,"timestamp":1789369201000,"preClose":238.62,"halted":0,"volume":2250449,"delay":0,"changeRate":0.0561,"floatShares":413000000,"shares":413000000,"eps":-3.8096,"marketStatus":"已收盘","change":13.38,"latestTime":"09-14 15:00:01","open":233.66,"high":252.7,"low":231.52,"amount":550000000,"amplitude":0.0888,"askPrice":252.01,"askSize":4,"bidPrice":252,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-3.8096,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"adjPreClose":238.62,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":262.48,"lowLimit":214.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":22.57,"roa":"--","roe":"--","epsLYR":-2.61,"committee":0.132075,"marketValue":104044000000,"turnoverRate":0.0055,"status":0,"afterMarket":{"amount":0,"volume":0,"close":252,"buyVolume":0,"sellVolume":800,"time":1789371237746,"indexStatus":"已收盘 09-14 15:30:00","preClose":238.62},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1789372800000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":104044000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2667592716","title":"9月14日百利天恒涨5.61%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667592716","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667592716?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:37","pubTimestamp":1789375069,"startTime":"0","endTime":"0","summary":"证券之星消息，9月14日百利天恒涨5.61%，收盘报252.0元，换手率0.55%，成交量2.25万手，成交额5.5亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共104家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为127.36亿元，最新净值1.8588，较上一交易日下跌2.06%，近一年下跌9.56%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","159760","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667365926","title":"百利天恒涨5.61%，开源证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667365926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667365926?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:37","pubTimestamp":1789375058,"startTime":"0","endTime":"0","summary":"今日百利天恒涨5.61%，收盘报252.0元。2026年8月28日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《公司信息更新报告：宜泽康商业化元年开启，核心管线进入全球加速期》，该研报对百利天恒给出“买入”评级。研报中预计2026-2028年营业收入分别为24.89/23.81/32.74亿元，PS分别为44.9/47.0/34.1倍，维持“买入”评级。百利天恒个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667687062","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren（HER2 ADC）在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667687062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667687062?lang=zh_cn&edition=full","pubTime":"2026-09-14 01:05","pubTimestamp":1789319113,"startTime":"0","endTime":"0","summary":"公司公告汇总四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告四川百利天恒药业股份有限公司自主研发的创新生物药注射用T-Bren联合帕妥珠单抗在HER2阳性乳腺癌新辅助治疗中的III期随机对照临床试验已完成首例受试者入组。该药物具有同类最佳潜力，已在全球范围内开展20项临床试验，覆盖多种HER2相关肿瘤适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667689797","title":"百利天恒最新公告：T-Bren联合帕妥珠单抗III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2667689797","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667689797?lang=zh_cn&edition=full","pubTime":"2026-09-13 15:39","pubTimestamp":1789285179,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗在HER2阳性乳腺癌新辅助治疗中对比多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗的III期随机对照临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展20项临床试验，覆盖乳腺癌、胃癌、肺癌、消化道肿瘤、泌尿系统肿瘤和妇科肿瘤等多项适应症。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300003185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507390","title":"每周股票复盘：百利天恒（688506）宜泽康III期临床完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507390","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507390?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:46","pubTimestamp":1789235173,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，百利天恒报收于238.62元，较上周的261.5元下跌8.75%。本周，百利天恒9月7日盘中最高价报263.57元。本周关注点来自公司公告汇总：宜泽康用于不可切除EGFR突变非小细胞肺癌维持治疗的III期临床试验完成首例受试者入组。来自公司公告汇总：百利天恒将参加2026年半年度科创板创新药行业集体业绩说明会，与投资者交流经营成果及发展战略。宜泽康是全球首创、新概念双抗ADC，已在中国和美国开展超45项临床试验，其中III期研究20项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666619805","title":"百利天恒（688506）披露宜泽康®III期临床试验完成首例受试者入组，9月10日股价上涨2.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666619805","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666619805?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:27","pubTimestamp":1789032452,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，百利天恒报收于245.64元，较前一交易日上涨2.2%，最新总市值为1014.18亿元。该股当日开盘240.91元，最高249.8元，最低239.34元，成交额达5.35亿元，换手率为0.53%。近日，四川百利天恒药业股份有限公司发布自愿披露公告，称其自主研发的宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。宜泽康是全球首创、新概念双抗ADC，已在中国和美国开展超45项临床试验，其中III期研究20项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589136","title":"百利天恒：宜泽康III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589136","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666589136?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:09","pubTimestamp":1788944940,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月9日，百利天恒公告称，公司自主研发的全球首创双抗ADC宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。每日经济新闻 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BMED","688506","MDTX","BK0239","PSYK","91194","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329543","title":"百利天恒跌3.34% 招商证券在历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329543","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665329543?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:36","pubTimestamp":1788860175,"startTime":"0","endTime":"0","summary":"中国经济网北京9月8日讯 百利天恒 今日收报244.56元，跌幅3.34%。 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260908/32363588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","91194","BK0010","688506","BK0183","BK0239","BK1564","BK0012","BK1147","06099","BK0188","600999","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665709364","title":"百利天恒：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665709364","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665709364?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:31","pubTimestamp":1788690660,"startTime":"0","endTime":"0","summary":"证券日报网讯9月6日，百利天恒发布公告称，公司计划于2026年9月16日15：00-17：00参加科创板2026年半年度创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KSTR","688506","BK0239","06978","IBBQ","BK1161","MEDX","91194","159992","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662498060","title":"开源证券：给予百利天恒买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662498060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662498060?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:53","pubTimestamp":1787918032,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,聂媛媛近期对百利天恒进行研究并发布了研究报告《公司信息更新报告：宜泽康商业化元年开启，核心管线进入全球加速期》，给予百利天恒买入评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家；过去90天内机构目标均价为336.12。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800048300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","161027","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662357039","title":"百利天恒（688506）2026年中报简析：增收不增利，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2662357039","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662357039?lang=zh_cn&edition=full","pubTime":"2026-08-28 06:20","pubTimestamp":1787869201,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百利天恒发布2026年中报。本报告期百利天恒三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达126.24%。本文数据来源于百利天恒2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800011027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662219724","title":"百利天恒连亏1年半 两募资共47.5亿元IPO国投证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2662219724","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662219724?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:47","pubTimestamp":1787798821,"startTime":"0","endTime":"0","summary":"中国经济网北京8月27日讯 百利天恒 昨日晚间发布2026年半年度报告。 百利天恒首次公开发行股票募集资金总额为99047.00万元，募集资金净额为88439.74万元。百利天恒2022年12年30日发布的招股说明书显示，该公司拟募集资金142227.55万元，分别用于抗体药物产业化建设项目、抗体药物临床研究项目。 百利天恒首次公开发行股票的发行费用合计为10607.26万元，其中，保荐及承销费用7900.00万元。 经计算，百利天恒上述两次募集资金金额合计为475,447.00万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32349294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["FRHC","161027","IPOS","KCE","91194","688506","BK0239","BK4127","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662254487","title":"百利天恒四闯港股：业绩过山车亏损加剧，董秘与证代接连离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2662254487","media":"市场资讯","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662254487?lang=zh_cn&edition=full","pubTime":"2026-08-27 08:20","pubTimestamp":1787790000,"startTime":"0","endTime":"0","summary":"据悉，2023年12月11日，百利天恒与百时美施贵宝订立独家许可及合作协议并于2024年2月8日生效，BMS同意支付8.00亿美元首付款及最多5.00亿美元或有近期付款，公司在达成若干开发、监管及销售业绩里程碑后，还有资格获得额外最多71.00亿美元的付款，潜在对价总额最高84.00亿美元。宜泽康的商业化潜力，是市场关注百利天恒估值的核心。刘盛宇认为，百利天恒2025年研发投入达到25亿元左右，说明公司是在用BD获得的资金继续押注后续管线","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-08-27/doc-inipthnz8950571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688506","BK4588","KCAI","BK0239","91194","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744556","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）用于局部晚期、复发或转移性HR+HER2-乳腺癌的III期临床试验的期中分析达到主要终点的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744556","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662744556?lang=zh_cn&edition=full","pubTime":"2026-08-27 04:10","pubTimestamp":1787775019,"startTime":"0","endTime":"0","summary":"公司公告汇总：宜泽康在HR+HER2-乳腺癌III期临床试验中期分析达到无进展生存期主要终点，为全球首个双抗ADC在此类适应症中达成主要终点的研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700009559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662171579","title":"百利天恒最新公告：上半年净亏损16.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662171579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662171579?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:39","pubTimestamp":1787744391,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司发布2026年半年度报告，实现营业收入1.87亿元，同比增长9.43%；归属于上市公司股东的净利润为亏损16.37亿元。注：公司Q2净利润亏损8.63亿，Q1净利润-7.75亿，据此计算，Q2净利润环比持续亏损。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600044101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736497","title":"百利天恒最新公告：宜泽康®乳腺癌III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736497?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655433,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的全球首创双抗ADC宜泽康(伦康依隆妥单抗)用于局部晚期、复发或转移性HR+HER2-乳腺癌的III期临床试验，在预设期中分析中达到无进展生存期(PFS)主要终点。这是该药第5个达主要终点的III期研究，也是全球首个双抗ADC在HR+HER2-乳腺癌治疗中达主要终点。目前，该药已有2项适应症获NMPA上市批准，1项NDA获CDE受理。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229322","title":"百利天恒：宜泽康现有产能可充分满足现阶段国内商业化与国内外临床需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661229322?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:36","pubTimestamp":1787556990,"startTime":"0","endTime":"0","summary":"证券之星消息，百利天恒08月24日在投资者关系平台上答复投资者关心的问题。宜泽康国内销售单价目前确定了吗？宜泽康作为公司自主研发的全球首款双抗ADC药物，现有产能可充分满足现阶段国内商业化与国内外临床需求，公司将结合后续市场情况做好产能保障。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400015457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661116252","title":"每周股票复盘：百利天恒（688506）BL-B01D1期中分析达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2661116252","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661116252?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:42","pubTimestamp":1787420532,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，百利天恒报收于282.71元，较上周的302.0元下跌6.39%。本周，百利天恒8月17日盘中最高价报307.8元。百利天恒当前最新总市值1167.24亿元，在化学制药板块市值排名3/149，在两市A股市值排名165/5210。目前该药已获NMPA批准用于鼻咽癌和食管鳞癌，三阴乳腺癌上市申请已获受理。公司已开展40余项临床试验，含20项III期研究，多项适应症获CDE突破性治疗认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661325043","title":"百利天恒依据首例给药临床试验确认17亿元里程碑收入，BMS尚未打款缺少实质性临床终点数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2661325043","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661325043?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:08","pubTimestamp":1787296080,"startTime":"0","endTime":"0","summary":"百利天恒，于2023年1月登陆上交所科创板。即使抛开上述的勾稽关系断裂不谈，该笔17.76亿元里程碑收入的确认时点同样令人费解，或涉嫌利用会计估计的自由裁量权提前确认收入以粉饰报表，或误导投资者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-21/doc-inipaenp6496930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MDTX","IBBJ","688506","BMED","91194","PSYK","BMS","BK0239","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489990","title":"百利天恒最新公告：双抗ADC肺癌III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489990","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660489990?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:57","pubTimestamp":1786960645,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的伦康依隆妥单抗用于EGFR敏感突变非小细胞肺癌的III期试验期中分析达PFS主要终点，OS有获益趋势。该药为全球首个且唯一获批上市的EGFR×HER3双抗ADC，已有4项III期研究达主要终点。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700024301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789418781699,"stockEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":-0.1656},{"period":"3month","weight":0.0718},{"period":"6month","weight":-0.0691},{"period":"1year","weight":-0.2796},{"period":"ytd","weight":-0.2201}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9075人(较上一季度增加16.69%)","perCapita":"45495股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}